PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32705692-7	2021	The DABI, RSV and ATV data suggest an impact of RI on intestinal P-gp, and potentially BCRP activity.	Dabigatran	4-8	phosphoglycolate phosphatase	Homo sapiens	65-69	
23210726-1	2013	AIM: The aim of this study was to develop a PK/PD model to assess drug-drug interactions between dabigatran and P-gp modulators, using the example of clarithromycin, a strong inhibitor of P-gp.	Dabigatran	97-107	phosphoglycolate phosphatase	Homo sapiens	112-116	
23210726-1	2013	AIM: The aim of this study was to develop a PK/PD model to assess drug-drug interactions between dabigatran and P-gp modulators, using the example of clarithromycin, a strong inhibitor of P-gp.	Dabigatran	97-107	phosphoglycolate phosphatase	Homo sapiens	188-192	
23210726-10	2013	CONCLUSION: The model proposed effectively describes the complex PK of dabigatran and takes into account drug-drug interactions with P-gp activity modulators, such as clarithromycin.	Dabigatran	71-81	phosphoglycolate phosphatase	Homo sapiens	133-137	
33073366-0	2021	Quantitative Benefit-Risk Assessment of P-gp Mediated Drug-Drug Interactions (DDIs) of Dabigatran Co-Administered with Pharmacokinetic Enhancers in Patients with Renal Impairment.	Dabigatran	87-97	phosphoglycolate phosphatase	Homo sapiens	40-44	
27943276-4	2017	The exception was dabigatran, which resulted in an approximately twofold higher magnitude for microdose compared to conventional dosing, and, thus, can be used to flag a worst-case scenario for P-gp.	Dabigatran	18-28	phosphoglycolate phosphatase	Homo sapiens	194-198	
30238965-0	2018	Dabigatran Etexilate and Digoxin: Comparison as Clinical Probe Substrates for Evaluation of P-gp Inhibition.	Dabigatran	0-20	phosphoglycolate phosphatase	Homo sapiens	92-96